CROWN: ctDNA Analyses Help Predict Early Progression With First-Line Lorlatinib in ALK+ NSCLC
Exploratory analysis from the phase 3 CROWN trial indicates that ctDNA features, such as TP53 mutations and methylation-based tumor fraction, can predict early progression in ALK-positive NSCLC patients treated with lorlatinib. These findings help identify patients at higher risk of resistance to first-line therapy.
Why it matters
Advancements in biomarker research improve personalized treatment strategies for lung cancer patients, potentially extending survival rates.
Baseline and on-treatment circulating tumor DNA (ctDNA) features, including TP53 mutations and methylation-based tumor fraction, were associated with early progression or prolonged progression-free survival (PFS) with first-line lorlatinib (Lorbrena) in patients with ALK-positive advanced non–small cell lung cancer (NSCLC), in exploratory analyses of the phase 3 CROWN trial (NCT03052608) presented at the 2026 European Society for Medical Oncology (ESMO) Congress.1
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in